>Mercado de tipificación de antígenos leucocitarios humanos (HLA) para trasplantes en América del Norte, por productos y servicios (reactivos y consumibles, instrumentos, software y servicios), tecnología (ensayos moleculares basados en secuenciación, tecnologías de ensayos moleculares, tecnologías de ensayos no moleculares), tipo de trasplante (trasplante de órganos sólidos, trasplante de células madre hematopoyéticas), aplicación (aplicaciones de diagnóstico, aplicación de investigación), usuario final (laboratorios de referencia independientes, hospitales y centros de trasplantes, laboratorios de investigación e institutos académicos), país (EE. UU., Canadá y México), tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de tipificación de antígenos leucocitarios humanos (HLA) para trasplantes en América del Norte
Se espera que el mercado de tipificación de antígeno leucocitario humano (HLA) para trasplantes de América del Norte gane un crecimiento significativo en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado de tipificación de antígeno leucocitario humano (HLA) para trasplantes de América del Norte está creciendo con una CAGR del 8,0% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 634,68 millones para 2028 desde USD 357,61 millones en 2020. La creciente demanda de procedimientos de trasplante de órganos está actuando como motor del crecimiento del mercado mundial de tipificación de leucocitos humanos para trasplantes.
La tipificación del antígeno leucocitario humano (HLA) se utiliza para emparejar a pacientes y donantes para trasplantes de médula ósea o sangre del cordón umbilical. Los HLA son proteínas (o marcadores) que se encuentran en la mayoría de las células del cuerpo. El sistema inmunitario utiliza estos marcadores para reconocer qué células pertenecen al cuerpo y cuáles no.
Las investigaciones han demostrado que un donante debe ser compatible con un mínimo de 6 marcadores HLA. Muchas veces se requiere una compatibilidad más cercana. La mejor compatibilidad se encuentra mediante pruebas detalladas. Como algunos tipos de HLA son más comunes que otros, algunos pacientes pueden enfrentar un mayor desafío para encontrar un donante compatible. Algunos tipos de HLA se encuentran con mayor frecuencia en ciertos grupos raciales y étnicos.
Una compatibilidad estrecha entre los marcadores HLA del donante y del paciente es esencial para un resultado exitoso del trasplante. La compatibilidad HLA promueve el crecimiento y desarrollo de nuevas células sanguíneas sanas (lo que se denomina injerto) y reduce el riesgo de una complicación posterior al trasplante llamada enfermedad de injerto contra huésped (EICH).
La alta demanda de donación de órganos, el aumento de innovaciones y tecnologías y el lanzamiento de nuevos productos también están impulsando el crecimiento del mercado de tipificación del antígeno leucocitario humano (HLA) para trasplantes en América del Norte.
Cada vez hay más personas afectadas por trastornos HLA que exigen un tratamiento altamente efectivo y avanzado para minimizar el riesgo durante el tratamiento. Los sistemas de atención médica necesitan medicamentos altamente avanzados para numerosos tipos diferentes de trastornos HLA durante el tratamiento de los pacientes. Por lo tanto, los principales actores del mercado se centran en gran medida en los lanzamientos y las aprobaciones de productos. Además, el gobierno y los organismos reguladores están apoyando a los actores del mercado en virtud de la aprobación de productos.
Rising product launches is acting as an opportunity for this market and is expected to impel the market growth for boosting the demand of global human leukocyte typing for transplant market.
Research on the human leukocyte antigen (HLA), is an extensively studied molecule involved in immunity and NGS technologies have revolutionised HLA typing procedure by providing fast and cost-effective technology. It is expected that lack skilled professionals is the major key challenge for the future growth of global human leukocyte antigen (HLA) typing for transplant market.
North America human leukocyte antigen (HLA) typing for transplant market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America Human Leukocyte Antigen (HLA) Typing for Transplant Market and Market Size
North America human leukocyte antigen (HLA) typing for transplant market is segmented on the basis of products and services, technology, transplant type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of by products and services, North America human leukocyte antigen (HLA) typing for transplant market is segmented in reagents and consumables, instruments, software and services. In 2021, instruments segment is expected to dominate the market due to rising product launches by the key market players.
- On the basis of technology, North America human leukocyte antigen (HLA) typing for transplant market is molecular assay technologies and non- molecular assay technologies. In 2021, molecular assay technologies segment is expected to dominate the market because of the rising success and greater improvement in post-transplant outcome.
- On the basis of transplant type, North America human leukocyte antigen (HLA) typing for transplant market is segmented solid organ transplant and haematopoietic stem cell transplant. In 2021, solid organ transplant segment is expected to dominate the market because it is most effective mode administration with better patient compliance.
- On the basis of application, the North America human leukocyte antigen (HLA) typing for transplant market is segmented into diagnostic applications and research application. In 2021, diagnostic applications segment is expected to dominate the market because the increased incidence of vital organ failure, doctors tend to detect problem prior via diagnostic applications.
- On the basis of end user, the North America human leukocyte antigen (HLA) typing for transplant market is segmented into independent reference laboratories, hospitals and transplant centres, research laboratories and academic institutes. In 2021, hospitals & transplant centers segment is expected to dominate the market owing to the high product launches in the market.
North America Human Leukocyte Antigen (HLA) Typing for Transplant Market Country Level Analysis
The North America human leukocyte antigen (HLA) typing for transplant market is analyzed and market size information is provided based on country, products and services, technology, transplant type, application, and end user.
Countries covered in the North America human leukocyte antigen (HLA) typing for transplant market report are U.S., Canada and Mexico.
U.S. is expected to dominate the North America human leukocyte antigen (HLA) typing for transplant market due to increasing government funding in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Healthcare Expenditure and Escalation in Innovations and Technologies in the North America Human Leukocyte Antigen (HLA) Typing for Transplant Market are Creating New Opportunities for Players in the North America Human Leukocyte Antigen (HLA) Typing for Transplant Market
North America human leukocyte antigen (HLA) typing for transplant market also provides you with detailed market analysis for every country growth in particular industry with the North America human leukocyte antigen (HLA) typing for transplant market sales, impact of advancement in the North America human leukocyte antigen (HLA) typing for transplant market and changes in regulatory scenarios with their support for the North America human leukocyte antigen (HLA) typing for transplant market in the period of 2011-2019.
Competitive Landscape and North America Human Leukocyte Antigen (HLA) Typing for Transplant Market Share Analysis
El panorama competitivo del mercado de tipificación de antígeno leucocitario humano (HLA) para trasplantes de América del Norte proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas relacionado con el mercado de tipificación de antígeno leucocitario humano (HLA) para trasplantes de América del Norte.
Los principales actores cubiertos en el informe son Thermo Fisher Scientific Inc., Illumina, Inc., Luminex Corporation, QIAGEN, CareDX, Inc., Immucor Inc., Bio Rad Labaratories, Inc., Takara Bio Inc., BD, Fujirebio, TBG Diagnostics Limited y GenDx.
Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Las empresas también inician numerosos lanzamientos de productos y firman acuerdos en todo el mundo, lo que acelera aún más el mercado de tipificación del antígeno leucocitario humano (HLA) para trasplantes en América del Norte.
Por ejemplo,
- En octubre de 2017, los kits HLAssure SE SBT de TBG recibieron la aprobación de la CFDA de China para uso clínico. Esta es la primera aprobación para un kit de tipificación de HLA de alta resolución en China. Esto ayudó a la empresa a fortalecer su presencia en China e impulsó el crecimiento del mercado.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT & SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING (USD)
4.2 PESTEL'S MODEL
4.3 PORTER'S 5 FORCES
5 REGIONAL SUMMARY
5.1 NORTH AMERICA
5.1.1 OVERVIEW
6 REGULATORY GUIDELINES FOR NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) FOR TRANSPLANT MARKET
6.1 U.S.
6.2 EUROPE
6.3 JAPAN
6.4 INDIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING DEMAND FOR ORGAN TRANSPLANT PROCEDURES
7.1.2 GROWING TECHNOLOGICAL ADVANCEMENT & INNOVATIONS IN HLA TYPING
7.1.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES IN HLA TYPING
7.1.4 INCREASING CERTAIN DISEASES SUCH AS BLOOD CANCERS, AND GENETIC BLOOD DISORDERS
7.2 RESTRAINTS
7.2.1 HIGH COST OF HLA TYPING FOR TRANSPLANTATION PROCEDURE
7.2.2 LIMITED REIMBURSEMENTS POLICIES FOR ORGAN TRANSPLANT
7.3 OPPORTUNITIES
7.3.1 PRODUCT LAUNCHES, AND AGREEMENT BY MAJOR PLAYERS
7.3.2 RISING GOVERNMENT FUNDING FOR ORGAN DONATIONS
7.3.3 RISING PUBLIC AWARENESS FOR ORGAN TRANSPLANTATION
7.4 CHALLENGES
7.4.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.4.2 DEARTH OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES
9.1 OVERVIEW
9.2 INSTRUMENTS
9.3 REAGENTS AND CONSUMABLES
9.4 SOFTWARE & SERVICES
10 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 MOLECULAR ASSAY TECHNOLOGIES
10.2.1 SEQUENCING-BASED MOLECULAR ASSAYS
10.2.1.1 NEXT-GENERATION SEQUENCING
10.2.1.2 SANGER SEQUENCING
10.2.1.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
10.2.2 PCR-BASED MOLECULAR ASSAYS
10.2.2.1 SEQUENCE-SPECIFIC PRIMER-PCR
10.2.2.2 REAL-TIME PCR
10.2.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
10.2.2.4 OTHER PCR-BASED MOLECULAR ASSAYS
10.3 NON-MOLECULAR ASSAY TECHNOLOGIES
11 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE
11.1 OVERVIEW
11.2 SOLID ORGAN TRANSPLANT
11.2.1 KIDNEY
11.2.2 LIVER
11.2.3 HEART
11.2.4 LUNG
11.2.5 PANCREAS
11.2.6 OTHERS
11.3 HEMATOPOIETIC STEM CELL TRANSPLANT
11.3.1 STEM CELL TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
12 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 DIAGNOSTIC APPLICATIONS
12.2.1 ANTIBODY SCREENING
12.2.2 CHIMERISM MONITORING
12.2.3 OTHERS
12.3 RESEARCH APPLICATIONS
13 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS & TRANSPLANT CENTERS
13.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
13.4 INDEPENDENT REFERENCE LABORATORIES
14 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 MARKET SHARE ANALYSIS: BY TECHNOLOGY
16.1 SEQUENCING BASED MOLECULAR ASSAYS
16.1.1 NORTH AMERICA
16.1.2 EUROPE
16.1.3 ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.2 NGS SEQUENCING
16.2.1 NORTH AMERICA
16.2.2 EUROPE
16.2.3 ASIA-PACIFIC
16.2.4 SOUTH AMERICA
16.2.5 MIDDLE EAST AND AFRICA
16.3 SANGER SEQUENCING
16.3.1 NORTH AMERICA
16.3.2 EUROPE
16.3.3 ASIA-PACIFIC
16.3.4 SOUTH AMERICA
16.3.5 MIDDLE EAST AND AFRICA
16.4 PCR BASED MOLECULAR ASSAYS
16.4.1 NORTH AMERICA
16.4.2 EUROPE
16.4.3 ASIA-PACIFIC
16.4.4 SOUTH AMERICA
16.4.5 MIDDLE EAST AND AFRICA
16.5 REAL TIME PCR
16.5.1 NORTH AMERICA
16.5.2 EUROPE
16.5.3 ASIA-PACIFIC
16.5.4 SOUTH AMERICA
16.5.5 MIDDLE EAST AND AFRICA
16.6 SEQUENCE-SPECIFIC PRIMER-PCR
16.6.1 NORTH AMERICA
16.6.2 EUROPE
16.6.3 ASIA-PACIFIC
16.6.4 SOUTH AMERICA
16.6.5 MIDDLE EAST AND AFRICA
16.7 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
16.7.1 NORTH AMERICA
16.7.2 EUROPE
16.7.3 ASIA-PACIFIC
16.7.4 SOUTH AMERICA
16.7.5 MIDDLE EAST AND AFRICA
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.1.6 SWOT ANALYSIS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.2.6 SWOT ANALYSIS
17.3 BIO-RAD LABORATORIES, INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.3.6 SWOT ANALYSIS
17.4 QIAGEN
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.4.5.1 ACQUISITION
17.4.6 SWOT ANALYSIS
17.5 ROCHE SEQUENCING (A SUBSIDIARY OF F.HOFFMAN LA-ROCHE LTD.)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.6 SWOT ANALYSIS
17.6 BD
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 BIOFORTUNA LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 CARE DX, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 CREATIVE BIOLABS
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.9.3.1 PRODUCT LAUNCH/UPDATE/APPROVAL
17.1 FUJIREBIO
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.10.4.1 CE CERTIFICATION
17.11 GENDX
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 IMMUCOR, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 PROUCT LAUNCH
17.13 LUMINEX CORPORATION
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 OMIXON INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PRODUCT LAUNCH
17.15 TAKARA BIO INC
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.15.4.1 LICENSING
17.15.5 PRODUCT LAUNCH
17.16 TBG DIAGNOSTICS LIMITED
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tablas
TABLE 1 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AVERAGE PRICE/TEST FOR HLA TYPING BY NEXT GENERATION SEQUENCING
TABLE 2 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BYPRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA REAGENTS AND CONSUMABLES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA SOFTWARE & SERVICES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY , 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA NON-MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE , 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA RESEARCH APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA HOSPITALS & TRANSPLANT CENTERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA RESEARCH LABORATORIES & ACADEMIC INSTITUTES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA OTHERS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 38 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 39 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 40 U.S. MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 41 U.S. SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 42 U.S. PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 43 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 44 U.S. SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 45 U.S. HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 46 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 47 U.S. DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 48 U.S. HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 49 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 50 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 51 CANADA MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 52 CANADA SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 53 CANADA PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 54 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 55 CANADA SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 56 CANADA HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 57 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 CANADA DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 60 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)
TABLE 61 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 62 MEXICO MOLECULAR ASSAY TECHNOLOGIES IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 63 MEXICO SEQUENCING-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 64 MEXICO PCR-BASED MOLECULAR ASSAYS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 65 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 66 MEXICO SOLID ORGAN TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 67 MEXICO HEMATOPOIETIC STEM CELL TRANSPLANT IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE, 2019-2028 (USD MILLION)
TABLE 68 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 MEXICO DIAGNOSTIC APPLICATIONS IN HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 70 MEXICO HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, BY END USERS, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET:
FIGURE 3 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SEGMENTATION
FIGURE 11 INCREASING DEMAND FOR ORGAN TRANSPLANTATION, AND RISING R&D ACTIVITIES IN HLA TYPING ARE EXPECTED TO DRIVE THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET, AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET
FIGURE 15 IN 2021, ESTIMATED NEW CASES OF LEUKEMIA, MYELOMA, AND LYMPHOMA IN THE U.S.
FIGURE 16 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2020
FIGURE 17 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, 2021-2028 (USD MILLION)
FIGURE 18 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, CAGR (2021-2028)
FIGURE 19 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 20 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2020
FIGURE 21 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 23 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 24 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2020
FIGURE 25 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, CAGR (2021-2028)
FIGURE 27 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2020
FIGURE 29 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 31 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, 2021-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: END USERS, CAGR (2021-2028)
FIGURE 35 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY END USERS, LIFELINE CURVE
FIGURE 36 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)
FIGURE 37 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2020)
FIGURE 38 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2021 & 2028)
FIGURE 39 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY REGION (2020 & 2028)
FIGURE 40 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)
FIGURE 41 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: SNAPSHOT (2020)
FIGURE 42 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020)
FIGURE 43 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 44 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 45 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: BY PRODUCT & SERVICES (2021-2028)
FIGURE 46 NORTH AMERICA HUMAN LEUKOCYTE ANTIGEN (HLA) TYPING FOR TRANSPLANT MARKET: COMPANY SHARE 2020 (%)
FIGURE 47 NORTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 48 EUROPE SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 49 ASIA-PACIFIC SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 50 SOUTH AMERICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 51 MIDDLE EAST AND AFRICA SEQUENCING BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 52 NORTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 53 EUROPE NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 54 ASIA-PACIFIC NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 55 SOUTH AMERICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 56 MIDDLE EAST AND AFRICA NGS SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 57 NORTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 58 EUROPE SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 59 ASIA-PACIFIC SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 60 SOUTH AMERICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 61 MIDDLE EAST AND AFRICA SANGER SEQUENCING: COMPANY SHARE 2020 (%)
FIGURE 62 NORTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 63 EUROPE PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 64 ASIA-PACIFIC PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 65 SOUTH AMERICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 66 MIDDLE EAST AND AFRICA PCR BASED MOLECULAR ASSAYS: COMPANY SHARE 2020 (%)
FIGURE 67 NORTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 68 EUROPE REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 69 ASIA-PACIFIC REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 70 SOUTH AMERICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 71 MIDDLE EAST AND AFRICA REAL TIME PCR: COMPANY SHARE 2020 (%)
FIGURE 72 NORTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 73 EUROPE SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 74 ASIA-PACIFIC SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 75 SOUTH AMERICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 76 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC PRIMER-PCR: COMPANY SHARE 2020 (%)
FIGURE 77 NORTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 78 EUROPE SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 79 ASIA-PACIFIC SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 80 SOUTH AMERICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
FIGURE 81 MIDDLE EAST AND AFRICA SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
